Atilotrelvir

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| INN =

| type =

| image = Atilotrelvir.svg

| alt =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| synonyms = GST-HG171

| CAS_number = 2850365-55-6

| PubChem = 167518234

| ChemSpiderID = 129309388

| UNII = JVV7PSN6VL

| DrugBank = DB19439

| IUPAC_name = (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1'-cyclopropane]-3-carboxamide

| C = 24| H = 32 | F = 3 | N = 5 | O = 4

| smiles = CC(C)(C)[C@@H](C(=O)N1[C@H]2C[C@@H]([C@H]1C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C4(C2)CC4)NC(=O)C(F)(F)F

| StdInChI = InChI=1S/C24H32F3N5O4/c1-22(2,3)17(31-21(36)24(25,26)27)20(35)32-14-9-15(23(10-14)5-6-23)16(32)19(34)30-13(11-28)8-12-4-7-29-18(12)33/h12-17H,4-10H2,1-3H3,(H,29,33)(H,30,34)(H,31,36)/t12-,13-,14-,15-,16-,17+/m0/s1

| StdInChI_comment =

| StdInChIKey = GTRJFXDJASEGSW-KBCNZALWSA-N

}}

Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19.{{cite journal | vauthors = Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, Zhang T, Tang Y, Lin F, Zhu F, Lin Y, Zeng Y, Zhang K, Yuan W, Liang Z, Sun R, Huo L, Hu P, Lin Y, Zhuang X, Wei Z, Chen X, Yan W, Yan X, Mu L, Lin Z, Tu X, Tan H, Huang F, Hu Z, Li H, Li G, Fu H, Yang Z, Chen X, Wang FS, Zhong N | title = Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial | journal = eClinicalMedicine | volume = 71 | pages = 102582 | date = May 2024 | pmid = 38618202 | pmc = 11015484 | doi = 10.1016/j.eclinm.2024.102582 }}{{cite journal | url = https://www.jsmcentral.org/sm-infectious-diseases/smjid685562.pdf | journal = SM Journal of Infectious Diseases | title = Discovery of GST-HG171, A Potent and Selective Oral 3CL Protease Inhibitor for the Treatment of COVID-19 | vauthors = Zhang G, Mao J, He H, Xu K, Zhou J, Yang Y, Li P, Du Y, Zhang H, Chen S, Lei W | volume = 6 | issue = 9 | date = 2023 }} It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).{{cite journal | vauthors = Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, Zhang T, Li C, Chen S, Li G, Zhang G, Ding Y, Liu L | title = Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171 | journal = Antimicrobial Agents and Chemotherapy | volume = 68 | issue = 1 | pages = e0111523 | date = January 2024 | pmid = 38099673 | pmc = 10777829 | doi = 10.1128/aac.01115-23 }}

In combination with ritonavir, it was approved for use in China in 2023.{{cite journal | vauthors = Zheng L, Wang W, Sun Q | title = Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA | journal = Signal Transduction and Targeted Therapy | volume = 9 | issue = 1 | pages = 46 | date = February 2024 | pmid = 38378623 | pmc = 10879080 | doi = 10.1038/s41392-024-01770-y }}